Here are six articles published by Becker's Hospital Review this week, highlighting supply chain leaders' importance in the C-suite and six upcoming regulatory decisions to watch for, among other topics.
- Prioritizing generics — 4 strategies for lower drug costs from Dr. Scott Gottlieb
Food and Drug Administration Commissioner Scott Gottlieb, MD, outlined his strategy to lower drug prices during a Monday interview with Bloomberg.
- 6 FDA decisions to keep an eye on in June
The Food and Drug Administration has approved 21 new drugs so far in 2017, with several regulatory decisions set to be made this month.
- UPMC Health Plan launches center for value-based drug purchasing
Pittsburgh-based UPMC Health Plan partnered with Express Scripts to develop the Center for Value-Based Purchasing for Pharmaceuticals.
- 3 obstacles to managing the non-acute supply chain — and 3 ways to overcome them
Healthcare supply chain leaders discuss the unique set of challenges associated with the non-acute supply chain and share management strategies that have proven successful at their own organizations.
- Companies perform better when supply pros are chiefs, not middle managers: 7 survey insights
Companies with supply chain leaders in the C-suite experience stronger operational performance than those where supply chain leaders take on a middle management role.
- Across enemy lines: Insurer recruits former drug reps to push more generics
Capital District Physicians' Health Plan in Albany, N.Y., is stepping up its fight against high drug prices with a new tactic — recruiting across enemy lines.
More articles on supply chain:
AstraZeneca divests migraine drug for $302M
Advocacy group calls for FDA action on Bayer's birth control device
Walmart pledges to slash supply chain greenhouse gas emission by 1B tons